New Entrants

Best Of

This page contains affiliate links. We may earn a commission at no extra cost to you — it never influences our rankings. See full disclosure below.

Best New Entrants of 2026: Providers Worth Watching

Compare GLP-1 Editorial Team

Not every new GLP-1 provider is chasing a trend without substance — some newer entrants are bringing genuinely differentiated offerings worth watching. Here's who's newly worth your attention in 2026.

MadeMed

New Entrant

MadeMed $167–$229

A newer platform offering both injectable and oral formats across semaglutide and tirzepatide, with a broader catalog than many single-format competitors.

Compounded formulations are not FDA-approved.

Visit MadeMed →Paid link

Ageless

New Entrant

Ageless From consult

A newer program positioned at the intersection of GLP-1 and broader longevity/hormone health — worth watching as combination-therapy demand grows.

Visit Ageless →Paid link

How we evaluate new entrants differently

Newer companies get more scrutiny in our methodology specifically because they haven't had time to build the track record established providers have — we watch for pricing stability, delivery on stated formats, and whether early clinical review quality holds up as they scale, rather than assuming a polished launch means a mature operation.

The honest caveat

"Worth watching" isn't the same endorsement as our established top performers — if company longevity matters to you, weigh that against what these newer entrants offer before committing to a longer-term relationship.

Ad Disclosure: We earn commission from featured providers. This never affects our rankings, which follow our published methodology. Medical Disclaimer: Informational only, not medical advice. Consult a licensed provider. Compounded medications are not FDA-approved.